

## **ALLEGATO A**

### **UNIVERSITÀ DEGLI STUDI DI MILANO**

Procedura di valutazione per la chiamata a professore di I fascia da ricoprire ai sensi dell'art. 24, comma 6, della Legge n. 240/2010 per il settore concorsuale 06/D2 - Endocrinologia, Nefrologia e Scienze della Alimentazione e del Benessere, settore scientifico-disciplinare MED/14 - Nefrologia, presso il Dipartimento di Scienze della Salute, Codice concorso 4372

**[Mario Gennaro Cozzolino]**  
**CURRICULUM VITAE**

### **INFORMAZIONI PERSONALI**

<b>COGNOME</b>	<b>COZZOLINO</b>
<b>NOME</b>	<b>MARIO GENNARO</b>
<b>DATA DI NASCITA</b>	<b>12/03/1969</b>

### **POSIZIONE ATTUALE**

Dal 1° febbraio 2015 Professore Associato per il settore scientifico disciplinare MED/14. Nefrologia presso il Dipartimento di Scienze della Salute dell'Università degli Studi di Milano.

Dal 1° giugno 2015 Direttore SC Nefrologia e Dialisi Ospedale San Paolo, Milano.

Dal 1 Dicembre 2018 Direttore SC Nefrologia e Dialisi ASST Santi Paolo e Carlo, Milano.

### **EDUCAZIONE UNIVERSITARIA E POST-UNIVERSITARIA**

**1994** Laurea in Medicina e Chirurgia, Università degli Studi di Milano (110/110).

**1999-2001:** "Research Assistant" presso Laboratorio di Vitamina D e Ormone Paratiroideo, Nefrologia, Dipartimento Medicina Interna. Washington University, Saint Louis, Missouri, USA.

**2000** Specializzazione in Nefrologia Medica, Università degli Studi di Milano (70/70 e lode).

**2006** Conseguitamento del Dottorato di Ricerca in "Fisiopatologia e Farmacologia Clinica e Terapia delle Malattie Metaboliche", Università degli Studi di Milano (pieni voti, giudizio ottimo).

**2006-2010** Professore a Contratto di Nefrologia presso la Scuola di Specializzazione di Nefrologia, Università degli Studi di Ferrara.

**2008-2010** Professore a Contratto di Nefrologia presso la Scuola di Specializzazione di Nefrologia, Università degli Studi di Milano.

Dal **2010** ad **oggi**. Responsabile del Laboratorio di Nefrologia Sperimentale presso il Dipartimento di Scienze della Salute, Università di Milano.

**2010-2014.** Ricercatore di Nefrologia presso Università degli Studi di Milano

**2013** Conseguitamento di Distinguished Fellowship of the European Renal Association

Dal **1° giugno 2015** al **30 settembre 2017**, Direttore Scuola di Specializzazione di Nefrologia Università di Milano.

**2017** Conseguitamento di Fellowship of the American Society of Nephrology

**2017** Conseguitamento Abilitazione Scientifica Nazionale per Professore di I Fascia di Nefrologia - Med/14.

**2019** Council Member of European Renal Association

## CURRICULUM PROFESSIONALE

Luglio-Settembre 1994: “Full-time visiting student”, presso la Sezione di Nefrologia, Dipartimento di Medicina, Saint Joseph Hospital. University of Chicago, Chicago, Illinois (USA). Direttore: Prof. Serafino Garella.

Agosto 1995-Luglio 1996: Borsa di Studio della Regione Lombardia, su: “Epidemiologia dell'insufficienza renale cronica nel territorio afferente all'Azienda Ospedaliera San Paolo, Milano”.

Agosto 1996-Gennaio 1997: Assistente Medico Nefrologo presso la Sezione di Emodialisi, Pio Albergo Trivulzio - Milano. (Primario: Prof. Giuseppe D'Amico).

Febbraio 1997 - Maggio 1998: Medico Specializzando in Nefrologia Medica presso la Divisione di Nefrologia, Dialisi e Trapianti di rene e rene-pancreas, Ospedale San Raffaele - Milano. (Direttore: Prof. Giuseppe Bianchi).

Giugno 1998-Ottobre 1999: Medico Specializzando in Nefrologia Medica presso la Divisione di Nefrologia e Dialisi, Azienda Ospedaliera San Paolo - Milano. (Primario: Prof. Diego Brancaccio).

Novembre 1999-Giugno 2002: “Research Assistant” presso il Laboratorio di Vitamina D e Ormone Paratiroideo, Divisione Renale, Dipartimento di Medicina Interna. Washington University, Saint Louis, Missouri, USA. (Direttore: Prof. Eduardo Slatopolsky).

Dal Luglio 2002 a Settembre 2010: Dirigente Medico I Livello presso l'Unità Operativa di Nefrologia e Dialisi - Azienda Ospedaliera San Paolo - Milano. (Direttore: Prof. Daniele Cusi).

Dal 1 Ottobre 2010 al 31 Gennaio 2015: Ricercatore per il settore scientifico disciplinare MED/14 Nefrologia presso il Dipartimento di Medicina, Chirurgia e Odontoiatria dell'Università degli Studi di Milano.

Dal 2011 al 2012: Membro del Collegio per il Corso di Dottorato di Fisiopatologia, Farmacologia, Clinica e Terapia delle Malattie Metaboliche, Università di Milano.

Dal 2013 al 2015: Membro del Collegio per il Corso di Dottorato di Medicina dei Sistemi, Università di Milano.

Dal 2016 ad oggi: Membro del Collegio per il Corso di Dottorato di Medicina Molecolare e Traslazionale, Università di Milano.

## AFFILIAZIONI E POSIZIONI ALL'INTERNO DI SOCIETÀ SCIENTIFICHE

Socio ordinario della Società Italiana di Nefrologia (SIN)

Socio ordinario della Società Europea di Nefrologia (ERA-EDTA)

Socio ordinario della Società Americana di Nefrologia (ASN)

Dal Giugno 2005 a Dicembre 2007: Membro del Gruppo di Stesura Linee Guida sul Metabolismo Minerale della Società Italiana di Nefrologia.

Dal Giugno 2006 al Settembre 2008: Segretario del Gruppo di Studio su “Elementi in Traccia e Metabolismo Minerale” della Società Italiana di Nefrologia.

Dal Gennaio 2007 a Dicembre 2009: Responsabile Area Calcio-Fosforo nella Commissione Standard Clinici, Comitato Governo Clinico della Società Italiana di Nefrologia

Da Ottobre 2010 a Settembre 2013: Membro del Consiglio Direttivo della Società Italiana di Nefrologia Sezione Lombarda.

Dal Settembre 2011 a Dicembre 2013: Coordinatore del Gruppo di Studio su “Metabolismo Minerale ed Elementi in Traccia” della Società Italiana di Nefrologia.

Da Ottobre 2012 a Dicembre 2018: Chairman del Working Group su CKD-MBD (Chronic Kidney Disease - Mineral Bone Disorder) dell'ERA-EDTA (European Renal Association - European Dialysis Transplantation Association)

Da Gennaio 2019 ad oggi: Advisor del Working Group su CKD-MBD (Chronic Kidney Disease - Mineral Bone Disorder) dell'ERA-EDTA (European Renal Association - European Dialysis Transplantation Association).

Da Giugno 2019 ad oggi: Council Member dell'ERA-EDTA (Società Europea di Nefrologia)

## **ATTIVITÀ CLINICA E ASSISTENZIALE**

Direttore Struttura Complessa Nefrologia e Dialisi ASST Santi Paolo e Carlo, Milano.

Dal 1991 ad ora ha appreso le seguenti competenze nell'ambito nefrologico:

- Reparto Nefrologico
- Ambulatorio Nefrologico
- Day Hospital Nefrologico
- Consulenze Nefrologiche
- Guardia attiva c/o il Servizio di Emodialisi
- Guardi attiva interdivisionale notturna di Medicina Interna
- Confezionamento di fistole artero-venose per emodialisi
- Posizionamento di cateteri venosi centrali

## **ATTIVITA' NEL DIPARTIMENTO DI SCIENZE DELLA SALUTE**

Membro del Consiglio di Biblioteca, Polo San Paolo (dal 2010)

Membro del Nucleo di Autovalutazione (nel 2011)

Delegato alla Ricerca (2015-2016)

## **ATTIVITA' DIDATTICA**

Responsabile Corso di Semeiotica e Patologia Apparati I, CdL Magistrale Medicina e Chirurgia, Polo S Paolo

Responsabile Corso Medicina Specialistica, CdL di Tecniche di fisiopatologia cardiocircolatoria e perfusione cardiovascolare

Docente di Nefrologia nel CdL di Fisioterapia

Docente di Nefrologia nel CdL di Dietistica.

Docente di Nefrologia nel CdL International Medical School

Docente di Nefrologia presso le Scuole di Specializzazione di Nefrologia, Medicina Nucleare, Radiologia, Radioterapia, Urologia, Ginecologia, Cardiologia presso Università di Milano.

Dal 2010: Lezioni frontali ed esercitazioni pratiche nel Corso di Semeiotica e Patologia degli Apparati I, Settore Disciplinare MED/14 - Nefrologia, presso i Poli Didattici Policlinico, San Giuseppe, San Donato Milanese, Humanitas, Facoltà di Medicina e Chirurgia, Università degli Studi di Milano.

Relatore a 34 Tesi e Correlatore a 3 Tesi di Laurea in Medicina e Chirurgia, Tesi di Specializzazione in Nefrologia, Tesi di Dottorato di Ricerca presso l'Università degli Studi di Milano.

Lezioni su invito presso diverse Università italiane e all'estero

*"Invited speaker"* a congressi della Società Italiana di Nefrologia, dell'American Society of Nephrology (ASN), International Society of Nephrology (ISN), European Dialysis and Transplant Association (EDTA).

Ha organizzato come direttore circa 60 Congressi, Seminari, Corsi di Aggiornamento per Medici sia in Italia che all'estero.

## ATTIVITA' DI RICERCA

Da circa 30 anni, si occupa della fisiopatologia e trattamento dell'iperparatiroidismo secondario in corso di insufficienza renale cronica. Inoltre, negli ultimi 20 anni si è interessato della patogenesi delle calcificazioni vascolari in corso di uremia.

Dal 2008 dirige l'attività di ricerca del Laboratorio di Nefrologia Sperimentale, presso il Dipartimento di Scienze della Salute, Università degli di Milano.

Dal 2009 al 2012 ha diretto il progetto europeo "Vitamin D Receptor Experts" che ha coinvolto quattro Università Europee (Milano, Barcellona, Amsterdam e Aachen), con lo scopo di organizzare meeting per ricercatori, dottorandi di ricerca e specializzandi, ottenere finanziamenti per la ricerca, favorire lo scambio tra giovani ricercatori tra le diverse università europee.

E' o è stato Principal Investigator dei seguenti studi:

EVOLVE: trial clinico randomizzato in doppio cieco per la valutazione dell'effetto del cinacalcet sugli eventi cardiovascolari nei pazienti in trattamento emodialitico.

CARISMA: trial a braccio singolo in aperto per valutare l'efficacia, la sicurezza e la tollerabilità dell'agente stimolante l'eritropoiesi di III generazione, CERA.

FARO-2: studio osservazionale retrospettivo sul trattamento dell'iperparatiroidismo secondario nei pazienti in dialisi.

IMPACT: studio di valutazione dell'efficacia di paracalcitolo e.v. sul controllo dell'iperparatiroidismo secondario vs. Cinacalcet + vitamina D a basse dosi nei pazienti in dialisi.

VITAVASK: studio randomizzato doppio-cieco dell'efficacia della vitamina K2 sul rallentamento della progressione delle calcificazioni coronariche dei pazienti in emodialisi.

PASCAL: studio su dosaggio di vitamina D, PTH, FGF23 su pazienti con malattia renale cronica.

Theranova Dialyzer and Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD): studio sull'uso di membrane di dialisi e parametri del metabolismo minerale.

Ha collaborato e/o collabora ai seguenti progetti di ricerca:

1. Patogenesi dell'iperplasia paratiroidea in corso di iperparatiroidismo secondario nel modello sperimentale del ratto uremico. Collaborazione con il Laboratorio di Vitamina D e Ormone Paratiroideo, Divisione Renale, Dipartimento di Medicina Interna. Washington University, Saint Louis, Missouri, USA. (Prof. Eduardo Slatopolsky, Prof.ssa Adriana Dusso).
2. Polimorfismo genico della Matrix-Gla Protein e della Fetuina e patologia cardio-vascolare in corso di insufficienza renale. Collaborazione con il Laboratorio di Analisi Chimico Cliniche e Microbiologiche, Università degli Studi di Milano, Polo Universitario San Paolo, Milano. (Dr.ssa Maria Luisa Biondi).
3. Polimorfismo genico della Metalloproteinasi-1 e della Metalloproteinasi-3 e patologia cardio-vascolare in corso di insufficienza renale. Collaborazione con il Laboratorio di Analisi Chimico Cliniche e Microbiologiche, Università degli Studi di Milano, Polo Universitario San Paolo, Milano. (Dr.ssa Maria Luisa Biondi).
4. Polimorfismo genico del Connective Tissue Growth Factor (CTGF, CCN2) e patologia cardio-vascolare in corso di insufficienza renale. Collaborazione con il Laboratorio di Analisi Chimico Cliniche e Microbiologiche, Università degli Studi di Milano, Polo Universitario San Paolo, Milano. (Dr.ssa Maria Luisa Biondi) e con il Department of Physiology and Biophysics, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA (Dr. Bruce Riser).
5. Meccanismi patogenetici delle calcificazioni extrascheletriche in corso di uremia. In particolare ruolo di fetuina e di Matrix Gla-Protein nell'inibizione del processo di calcificazione. Collaborazione con la Cattedra di Nefrologia, Università degli Studi Federico II di Napoli. (Prof. Domenico Russo, Prof. Bruno Memoli).
6. Studio dell'imaging delle calcificazioni vascolari nei pazienti in dialisi. Collaborazione con la Divisione di Cardiologia, Emory University, Atlanta, Georgia, USA (Prof. Paolo Raggi).
7. Fisiopatologia dell'iperparatiroidismo secondario nel paziente emodializzato.

- Collaborazione con il Laboratorio di Farmacologia, Università degli Studi di Milano, Polo Universitario San Paolo, Milano. (Prof. Alfredo Gorio, Prof.ssa Anna Maria Di Giulio).
8. Funzione endoteliale nei pazienti emodializzati. Collaborazione con la Divisione di Cardiologia, Università degli Studi di Milano, Polo Universitario San Paolo, Milano. (Prof. Marco Guazzi).
  9. Terapia dell'iperfosforemia e dell'iperparatiroidismo secondario nel paziente uremico. Sviluppo di nuovi farmaci. Studi monocentrici e multicentrici con nuovi chelanti del fosforo e nuovi analoghi della vitamina D.
  10. Sviluppo di nuove membrane di emodialisi. Expended Haemodialysis. Collaborazione con Prof. Claudio Ronco, Università di Padova.

## **PREMI**

Nel **2003** ha ricevuto un Premio durante il World Congress of Nephrology di Berlino come uno tra i 10 "WCN 2003 Awards for Best Abstracts".

Nel **2006** ha ricevuto un Premio durante il 47° Congresso della Società Italiana di Nefrologia come uno tra i 3 migliori abstract sul tema "Dialisi".

Nel **2007** ha ricevuto un Premio durante il 48° Congresso della Società Italiana di Nefrologia come il miglior lavoro sul tema "Metabolismo Calcio e Fosforo"

Nel **2013**, basato su Expertscape's, un'analisi multifattoriale delle pubblicazioni scientifiche del decennio 2003-2013, è stato inserito come uno dei primi 5 ricercatori al mondo nel campo dell'iperparatiroidismo.

Dal **2015** al **2019**, basato su Expertscape's, un'analisi multifattoriale delle pubblicazioni scientifiche del decennio 2005-2015, è stato inserito come primo ricercatore al mondo nel campo dell'iperparatiroidismo.

Nel **2016** è vincitore del Grant Application for Baxter In-Center Hemodialysis per il progetto "Molecular and cellular mechanism of vascular ageing in chronic kidney disease: role of TheraNova dialyzer on mineral metabolism disorder, oxidative stress and vascular calcification" (\$72,000.00 USD).

## **ATTIVITA' EDITORIALE**

Dal 1° Gennaio **2006** fa parte dell'Editorial Board del "Giornale Italiano di Nefrologia", nella Sezione Uremia.

Nel **2009** è stato revisore delle "KDIGO Clinical Practice Guidelines for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)".

Dal **2011** fa parte dell'Editorial Board di PlosOne, Scientific Reports, Clinical Kidney Journal, Blood Purification, Nephron Clinical Practice e Giornale Italiano di Nefrologia.

E' attualmente "peer reviewer" per circa 40 riviste internazionali.

## PUBBLICAZIONI

(di cui 288 recensite su med-lines internazionali)

*Impact Factor Totale: 760*

*H-index: 35 (Scopus);45 (Google Scholar)*

1. Roggeri A, Conte F, Rossi C, **Cozzolino M**, Zocchetti C, Roggeri DP. Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs. *Drugs Context*. **2020** Mar 27;9. pii: 2020-1-1. doi: 10.7573/dic.2020-1-1. eCollection 2020.
2. **Cozzolino M**, Ketteler M, Wagner CA. An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations. *Expert Opin Ther Targets*. **2020** Mar 19:1-12. doi: 10.1080/14728222.2020.1743680. [Epub ahead of print]
3. **Cozzolino M**, Ciceri P. Ectopic Calcification in Uremia: Where Do We Stand? *Blood Purif*. **2020** Feb 19:1-2. doi: 10.1159/000506178. [Epub ahead of print]
4. **Cozzolino M**, Lari C, Stocco M. The Home Jail Haemodialysis: a simple way to save money and improve security. *Clin Kidney J*. 2019 Oct 19;13(1):113. doi: 10.1093/ckj/sfz149. eCollection 2020 Feb.
5. Musso CG, Enz PA, Kowalczyk A, **Cozzolino M**, Brandenburg V, Nigwekar S. Differential diagnosis of calciphylaxis in chronic dialysis patients. *Int Urol Nephrol*. **2020** Feb 1. doi: 10.1007/s11255-020-02388-z. [Epub ahead of print]
6. Bellasi A, **Cozzolino M**, Malberti F, Cancarini G, Esposito C, Guastoni CM, Ondei P, Pontoriero G, Teatini U, Vezzoli G, Pasquali M, Messa P, Locatelli F. New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology. *J Nephrol*. **2019** Dec 18. doi: 10.1007/s40620-019-00677-0. [Epub ahead of print]
7. **Cozzolino M**, Fusaro M, Ciceri P, Gasperoni L, Cianciolo G. The Role of Vitamin K in Vascular Calcification. *Adv Chronic Kidney Dis*. **2019** Nov;26(6):437-444. doi: 10.1053/j.ackd.2019.10.005. Review.
8. Ciceri P, Falleni M, Tosi D, Martinelli C, Cannizzo S, Marchetti G, D'Arminio Monforte A, Bulfamante G, Block GA, Messa P, **Cozzolino M**. Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis. *Int J Mol Sci*. **2019** Nov 25;20(23). pii: E5925. doi: 10.3390/ijms20235925.
9. Capelli I, Cianciolo G, Gasperoni L, Galassi A, Ciceri P, **Cozzolino M**. NUTRITIONAL VITAMIN D IN CKD: SHOULD WE MEASURE ? SHOULD WE TREAT? *Clin Chim Acta*. **2019** Nov 23. pii: S0009-8981(19)32123-0. doi: 10.1016/j.cca.2019.11.010. [Epub ahead of print]
10. **Cozzolino M**, Ketteler M. Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD). *Expert Opin Pharmacother*. **2019** Nov 1:1-13. doi: 10.1080/14656566.2019.1663826.[Epub ahead of print]
11. Ciceri P, Falleni M, Tosi D, Martinelli C, Bulfamante G, Block GA, Messa P, **Cozzolino M**. High-phosphate induced vascular calcification is reduced by iron citrate through inhibition of extracellular matrix osteo-chondrogenic shift in VSMCs. *Int J Cardiol*. **2019** Oct 8. pii: S0167-5273(19)32387-3. doi:10.1016/j.ijcard.2019.09.068. [Epub ahead of print]

12. Fusaro M, Holden R, Lok C, Iervasi G, Plebani M, Aghi A, Gallieni M, **Cozzolino M**. Phosphate and bone fracture risk in chronic kidney disease patients. *Nephrol Dial Transplant*. **2019** Oct 17. pii: gzf196. doi: 10.1093/ndt/gfz196. [Epub ahead of print]
13. Roggeri DP, Roggeri A, Zocchetti C, **Cozzolino M**, Rossi C, Conte F. Real world data on healthcare resource consumption and costs before and after kidney transplantation. *Clin Transplant*. **2019** Oct 6:e13728. doi: 10.1111/ctr.13728. [Epub ahead of print]
14. Bover J, **Cozzolino M**. Small steps towards the potential of 'preventive' treatment of early phosphate loading in chronic kidney disease patients. *Clin Kidney J*. **2019** Jul 25;12(5):673-677. doi: 10.1093/ckj/sfz082. eCollection 2019 Oct.
15. Li J, Sun S, Han M, Wang L, Liao R, Xiong Y, Li Y, Jiang H, Qin Z, Maharjan A, **Cozzolino M**, Zarbock A, Su B. The effects of citrate dialysate in hemodialysis on polymorphonuclear elastase interaction with tissue factor and its inhibitor. *Ann Transl Med*. **2019** Aug;7(16):391. doi: 10.21037/atm.2019.07.57.
16. Alfieri C, Ruzhytska O, Vettoretti S, Caldiroli L, **Cozzolino M**, Messa P. Native Hypovitaminosis D in CKD Patients: From Experimental Evidence to Clinical Practice. *Nutrients*. **2019** Aug 15;11(8). pii: E1918. doi: 10.3390/nu11081918. Review.
17. Galassi A, Perna F, De Nicola E, Moneghini L, Sganzaroli AB, **Cozzolino M**. Calciphylaxis in a dialysis patient treated by intralesional and systemic sodium thiosulphate on top of multifactorial intervention. *Clin Kidney J*. **2018** Dec 10;12(4):546-549. doi: 10.1093/ckj/sfy119. eCollection **2019** Aug.
18. Galassi A, Ciceri P, Fasulo E, Carugo S, Cianciolo G, **Cozzolino M**. Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly. *Drugs Aging*. **2019** Jul 15. doi: 10.1007/s40266-019-00696-3. [Epub ahead of print]
19. Tedesco M, Gallieni M, Pellegata F, **Cozzolino M**, Alberici F. Update on ANCA-associated vasculitis: from biomarkers to therapy. *J Nephrol*. **2019** Jul 12. doi: 10.1007/s40620-019-00628-9. [Epub ahead of print] Review.
20. Foletti A, Baron P, **Cozzolino M**. Biophysical integrated approach for the management of early stages of CKD in elderly patients: a 12-month controlled study. *Int Urol Nephrol*. **2019** Jul 1. doi: 10.1007/s11255-019-02212-3. [Epub ahead of print]
21. Afsar B, Sag AA, Oztosun C, Kuwabara M, **Cozzolino M**, Covic A, Kanbay M. The role of uric acid in mineral bone disorders in chronic kidney disease. *J Nephrol*. **2019** Apr 27. doi: 10.1007/s40620-019-00615-0. [Epub ahead of print] Review.
22. Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R, Aparicio C, Lecchi V, Perna A, Peraro F, Villa D, Ferrari S, Cannata A, Mazzaferro S, Mallamaci F, Zoccali C, Bellasi A, **Cozzolino M**, Remuzzi G, Ruggenti P, Kohan DE; ANSWER Study Organization. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. *Am J Kidney Dis*. **2019** Apr 23. pii: S0272-6386(19)30136-2. doi: 10.1053/j.ajkd.2019.01.029. [Epub ahead of print]
23. Ureña-Torres PA, Vervloet M, Mazzaferro S, Oury F, Brandenburg V, Bover J, Cavalier E, Cohen-Solal M, Covic A, Drüeke TB, Hindié E, Evenepoel P, Frazão J, Goldsmith D, Kazama JJ, **Cozzolino M**, Massy ZA; ERA-EDTA CKD-MBD Working Group. Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. *Clin Kidney J*. **2018** Jul 20;12(2):269-280. doi: 10.1093/ckj/sfy061. eCollection 2019 Apr.
24. **Cozzolino M**, Ciceri P, Galassi A, Mangano M, Carugo S, Capelli I, Cianciolo G. The Key Role of Phosphate on Vascular Calcification. *Toxins (Basel)*. **2019** Apr 9;11(4). pii: E213. doi: 10.3390/toxins11040213. Review.

25. **Cozzolino M**, Ciceri P, Galassi A. Hyperphosphatemia: a novel risk factor for mortality in chronic kidney disease. *Ann Transl Med.* **2019** Feb;7(3):55. doi: 10.21037/atm.2018.06.50.
26. Ciceri P, Galassi A, Alfieri C, Messa P, **Cozzolino M**. Uremic Patients with Increased Vascular Calcification Score Have Serum with High Calcific Potential: Role of Vascular Smooth Muscle Cell Osteoblastic Differentiation and Apoptosis. *Blood Purif.* **2019** Feb 6:1-8. doi: 10.1159/000497229. [Epub ahead of print]
27. **Cozzolino M**, Mangano M, Galassi A, Ciceri P, Messa P, Nigwekar S. Vitamin K in Chronic Kidney Disease. *Nutrients.* **2019** Jan 14;11(1). pii: E168. doi: 10.3390/nu11010168. Review.
28. Portales-Castillo I, Kroshinsky D, Malhotra CK, Culbert-Costley R, **Cozzolino MG**, Karparis S, Halasz CL, Gorman J, Manley HJ, Malhotra R, Nigwekar SU. Calciphylaxis-as a drug induced adverse event. *Expert Opin Drug Saf.* **2018** Dec 21. doi: 10.1080/14740338.2019.1559813. [Epub ahead of print]
29. Ierardi AM, Petrillo M, Coppola A, Angileri SA, Galassi A, Padovano B, Volpi A, **Cozzolino M**, Carrafiello G. Percutaneous microwave ablation of renal angiomyolipomas in tuberous sclerosis complex to improve the quality of life: preliminary experience in an Italian center. *Radiol Med.* **2018** Dec 11. doi: 10.1007/s11547-018-0967-3. [Epub ahead of print]
30. Volpi A, Sala G, Lesma E, Labriola F, Righetti M, Alfano RM, **Cozzolino M**. Tuberous sclerosis complex: new insights into clinical and therapeutic approach. *J Nephrol.* **2018** Nov 7. doi: 10.1007/s40620-018-0547-6. [Epub ahead of print] Review.
31. Di Lullo L, Ronco C, Granata A, Paoletti E, Barbera V, **Cozzolino M**, Ravera M, Fusaro M, Bellasi A. Chronic Hyperkalemia in Cardiorenal Patients: Risk Factors, Diagnosis, and New Treatment Options. *Cardiorenal Med.* **2018** Oct 25;9(1):8-21. doi: 10.1159/000493395. [Epub ahead of print] Review.
32. **Cozzolino M**, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. *Nephrol Dial Transplant.* **2018** Oct 1;33(suppl\_3):iii28-iii34. doi: 10.1093/ndt/gfy174.
33. Alfieri C, Malberti F, Mazzaferro S, Gallieni M, Russo D, Messa P, **Cozzolino M**. [Hyperphosphatemia in dialysis: which binder?]. *G Ital Nefrol.* **2018** Sep;35(5). pii: 2018-vol5. Italian.
34. Alfieri C, Regalia A, Zanoni F, Vettoretti S, **Cozzolino M**, Messa P. The Importance of Adherence in the Treatment of Secondary Hyperparathyroidism. *Blood Purif.* **2018** Sep 17:1-8. doi: 10.1159/000492918. [Epub ahead of print] Review.
35. Mazzaferro S, Tartaglione L, Cascone C, Di Daniele N, Pani A, Morosetti M, Francisco M, Nordio M, Leonardi M, Martello M, Grimaldi C, **Cozzolino M**, Rotondi S, Pasquali M; Italian Study Group on Mineral Metabolism. Multicenter study on parathyroidectomy (PTX) in Italy: preliminary results. *J Nephrol.* **2018** Aug 28. [Epub ahead of print]
36. Borrelli S, Chiodini P, De Nicola L, Minutolo R, Provenzano M, Garofalo C, Remuzzi G, Ronco C, **Cozzolino MG**, Manno C, Costanzo AM, Gualberti G, Conte G. Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care. *PLoS One.* **2018** Aug 23;13(8):e0202417.
37. **Cozzolino M**, Bolasco P, Ronco C, Conte G, Menè P, Mereu MC, Di Luca M, Roccatello D, Rosati A, Jommi C, Costanzo AM, Gualberti G, di Luzio Paparatti U, Remuzzi G. Clinical Management of Chronic Kidney Disease Patients in Italy: Results from the IRIDE Study. *Nephron.* **2018** Jul 17:1-9.[Epub ahead of print]



38. Bellasi A, **Cozzolino M**, Malberti F, Cancarini G, Esposito C, Genderini A, Guastoni CM, Ondei P, Pontoriero G, Teatini U, Vezzoli G, Messa P, Locatelli F. [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists from Lombardy]. *G Ital Nefrol*. **2018** May;35(3). pii: 2018-vol3. Italian.
39. Ureña-Torres PA, **Cozzolino M**, Bover J. [Utilization of alfacalcidol and active vitamin D analogs in chronic kidney disease]. *Nephrol Ther*. **2018** Mar 12. pii: S1769-7255(17)30549-7. doi: 10.1016/j.nephro.2017.03.003. [Epub ahead of print]French.
40. Bover J, Ureña P, Aguilar A, Mazzaferro S, Benito S, López-Báez V, Ramos A, daSilva I, **Cozzolino M**. Alkaline Phosphatases in the Complex Chronic Kidney Disease-Mineral and Bone Disorders. *Calcif Tissue Int*. **2018** Feb 14. doi: 10.1007/s00223-018-0399-z. [Epub ahead of print]
41. **Cozzolino M**. CKD-MBD KDIGO guidelines: how difficult is reaching the 'target'? *Clin Kidney J*. **2018** Feb;11(1):70-72.
42. Jommi C, Armeni P, Battista M, di Procolo P, Conte G, Ronco C, **Cozzolino M**, Costanzo AM, di Luzio Paparatti U, Concas G, Remuzzi G; IRIDE Study Group. The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study. *Pharmacoecon Open*. **2017** Dec 4. doi: 10.1007/s41669-017-0062-z. [Epub ahead of print]
43. **Cozzolino M**, Messa P. Treatments for secondary hyperparathyroidism in hemodialysis. *Pol Arch Intern Med*. **2017** Dec 22;127(12):807-809.
44. **Cozzolino M**. Achieve Your Goals Together. The Easy and Reasonable Way to Treat Chronic Kidney Disease-Mineral Bone Disorder. *Blood Purif*. **2017** Dec 7;45(1-3):71-72.
45. Genovesi S, Nava E, Pasa A, Corghi E, Ondei P, Marta E, Bellasi A, Malberti F, Teatini U, Guastoni CM, Spatola L, Luise MC, Tiboldo R, Bertoli S, Messa P, Doria M, Gallieni M, **Cozzolino M**, Spotti D, Sala V, Sironi E, Boriani G. [Clinical practice for the diagnosis of cardiac arrhythmias in patients on renal replacement therapy: data from a Lombard survey]. *G Ital Nefrol*. **2017** Dec 5;34(Nov-Dec). pii: 2017-vol6. Italian.
46. Covic A, Vervloet M, Massy ZA, Torres PU, Goldsmith D, Brandenburg V, Mazzaferro S, Evenepoel P, Bover J, Apetrii M, **Cozzolino M**. Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. *Lancet Diabetes Endocrinol*. **2017** Oct 16. [Epub ahead of print] Review.
47. Di Lullo L, Ronco C, Bellasi A, **Cozzolino M**, Floccari F, Barbera V, Verdesca S, Rivera R, De Pascalis A, Mudoni A, Santoro A. [Nephrilysin inhibition and chronic kidney disease]. *G Ital Nefrol*. **2017** Sep 28;34(5):102-112. Review. Italian.
48. Castini D, Persampieri S, Floreani R, Galassi A, Biondi ML, Carugo S, **Cozzolino M**. Troponin I Levels in Asymptomatic Hemodialysis Patients. *Blood Purif*. **2017** Sep 29;44(3):236-243. doi: 10.1159/000480225. [Epub ahead of print]
49. Mazzaferro S, Massy ZA, Vervloet M, **Cozzolino M**. Bone in CKD: why the ERA EDTA CKD-MBD working group organized a dedicated meeting? *J Nephrol*. **2017** Sep 23. doi: 10.1007/s40620-017-0436-4. [Epub ahead of print]
50. **Cozzolino M**, Galassi A, Pivari F, Ciceri P, Conte F. The Cardiovascular Burden in End-Stage Renal Disease. *Contrib Nephrol*. **2017**;191:44-57. doi: 10.1159/000479250. Epub 2017 Sep 14. PubMed PMID: 28910790.
51. Shroff R, Wan M, Nagler EV, Bakaloglu S, **Cozzolino M**, Bacchetta J, Edefonti A, Stefanidis CJ, Vande Walle J, Ariceta G, Klaus G, Haffner D, Schmitt CP; European Society for Paediatric Nephrology Chronic Kidney Disease Mineral and Bone Disorders and Dialysis Working Groups. Clinical practice recommendations for treatment with active

- vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis. *Nephrol Dial Transplant*. **2017** Jul 1;32(7):1114-1127. doi: 10.1093/ndt/gfx080.
52. Shroff R, Wan M, Nagler EV, Bakkaloglu S, Fischer DC, Bishop N, **Cozzolino M**, Bacchetta J, Edefonti A, Stefanidis CJ, Vande Walle J, Haffner D, Klaus G, Peter Schmitt C; European Society for Paediatric Nephrology Chronic Kidney Disease Mineral and Bone Disorders and Dialysis Working Groups. Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis. *Nephrol Dial Transplant*. **2017** Jul 1;32(7):1098-1113. doi: 10.1093/ndt/gfx065.
  53. Galassi A, Bellasi A, Ciceri P, Pivari F, Conte F, **Cozzolino M**. Calcifediol to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease. *Expert Rev Clin Pharmacol*. **2017** Aug 28. doi: 10.1080/17512433.2017.1371011. [Epub ahead of print]
  54. Giannini S, Mazzaferro S, Minisola S, De Nicola L, Rossini M, **Cozzolino M**. Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion. *Endocrine*. **2017** Jul 19. doi: 10.1007/s12020-017-1369-3. [Epub ahead of print] Review.
  55. Di Lullo L, Barbera V, Bellasi A, **Cozzolino M**, Russo D, Otranto G, Santoboni F, Ronco C. [Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation]. *G Ital Nefrol*. **2017** Apr;34(2):58-73. Italian.
  56. Di Lullo L, Barbera V, Bellasi A, **Cozzolino M**, Russo D, Otranto G, Santoboni F, Ronco C. [NOACs and Chronic kidney disease]. *G Ital Nefrol*. **2017** Mar;34(Suppl 69):188-204. Italian. PubMed
  57. Bellasi A, Mangano M, Galassi A, **Cozzolino M**. [CKD-MBD, cardiovascular involvement and prognosis]. *G Ital Nefrol*. **2017** Mar;34(Suppl 69):150-161. Italian.
  58. **Cozzolino M**, Galassi A, Conte F, Mangano M, Di Lullo L, Bellasi A. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide. *Ther Clin Risk Manag*. **2017** Jun 1;13:679-689.
  59. **Cozzolino M**, Foque D, Ciceri P, Galassi A. Phosphate in Chronic Kidney Disease Progression. *Contrib Nephrol*. **2017**;190:71-82. doi: 10.1159/000468915. Epub 2017 May 23.
  60. Di Lullo L, Ronco C, **Cozzolino M**, Russo D, Russo L, Di Iorio B, De Pascalis A, Barbera V, Galliani M, Vitaliano E, Campana C, Santoboni F, Bellasi A. Non vitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. *Thromb Res*. **2017** May 4;155:38-47. doi: 10.1016/j.thromres.2017.04.027. [Epub ahead of print] Review.
  61. Bellasi A, Galassi A, Mangano M, Di Lullo L, **Cozzolino M**. Vitamin D metabolism and potential effects of vitamin D receptor modulation in chronic kidney disease. *Curr Drug Metab*. **2017** Apr 26. doi: 10.2174/1389200218666170427112735. [Epub ahead of print]
  62. Di Lullo L, Bellasi A, Barbera V, Russo D, Russo L, Di Iorio B, **Cozzolino M**, Ronco C. Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate. *Indian Heart J*. **2017** Mar - Apr;69(2):255-265. doi: 10.1016/j.ihj.2017.01.005. Epub 2017 Jan 22. Review.
  63. Bover J, Bailone L, López-Báez V, Benito S, Ciceri P, Galassi A, **Cozzolino M**. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. *J Nephrol*. **2017** Apr 21. doi: 10.1007/s40620-017-0404-z. [Epub ahead of print] Review.
  64. Cianciolo G, Galassi A, Capelli I, Schillaci R, La Manna G, **Cozzolino M**. Klotho-FGF23, cardiovascular disease, and vascular calcification: black or white? *Curr Vasc Pharmacol*. **2017** Mar 9. doi: 10.2174/1570161115666170310092202. [Epub ahead of print]

65. Evenepoel P, D'Haese P, Bacchetta J, Cannata-Andia J, Ferreira A, Haarhaus M, Mazzaferro S, Lafage Proust MH, Salam S, Spasovski G, **Cozzolino M**; ERA-EDTA Working Group on CKD-MBD.. Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative-a position paper. *Nephrol Dial Transplant*. **2017** Mar 3. doi: 10.1093/ndt/gfw468. [Epub ahead of print]
66. Di Lullo L, Mangano M, Ronco C, Barbera V, De Pascalis A, Bellasi A, Russo D, Di Iorio B, **Cozzolino M**. The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents. *Diabetes Metab Syndr*. **2017** Mar 6. pii: S1871-4021(17)30064-4. doi: 10.1016/j.dsx.2017.03.005. [Epub ahead of print] Review.
67. Di Lullo L, Ronco C, Barbera V, **Cozzolino M**, Santoboni F, Villani A, De Pascalis A, Bellasi A. [Newer anti - diabetic therapies and chronic kidney disease]. *G Ital Nefrol*. **2017** Jan-Feb;34(1).
68. Vervloet M, **Cozzolino M**. Vascular calcification in chronic kidney disease: different bricks in the wall? *Kidney Int*. **2017** Apr;91(4):808-817. doi: 10.1016/j.kint.2016.09.024. Review.
69. Vervloet MG, Sezer S, Massy ZA, Johansson L, **Cozzolino M**, Fouque D; ERA-EDTA Working Group on Chronic Kidney Disease-Mineral and Bone Disorders and the European Renal Nutrition Working Group. The role of phosphate in kidney disease. *Nat Rev Nephrol*. **2017** Jan;13(1):27-38. doi: 10.1038/nrneph.2016.164. Review.
70. Massy ZA, Nistor I, Apetrii M, Brandenburg VM, Bover J, Evenepoel P, Goldsmith D, Mazzaferro S, Urena-Torres P, Vervloet MG, **Cozzolino M**, Covic A, Era-Edta WG. Magnesium-based interventions for normal kidney function and chronic kidney disease. *Magnes Res*. **2016** Dec 22. doi: 10.1684/mrh.2016.0412. [Epub ahead of print]
71. Di Lullo L, Bellasi A, Russo D, **Cozzolino M**, Ronco C. Cardiorenal acute kidney injury: Epidemiology, presentation, causes, pathophysiology and treatment. *Int J Cardiol*. **2016** Nov 9;227:143-150
72. Kanbay M, Vervloet M, **Cozzolino M**, Siriopol D, Covic A, Goldsmith D, Solak Y. Novel Faces of Fibroblast Growth Factor 23 (FGF23): Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury. *Calcif Tissue Int*. **2016** Nov 9. [Epub ahead of print]
73. Bellasi A, Di Micco L, Santoro D, Marzocco S, De Simone E, **Cozzolino M**, Di Lullo L, Guastaferro P, Di Iorio B; UBI study investigators.. Correction of metabolic acidosis improves insulin resistance in chronic kidney disease. *BMC Nephrol*. **2016** Oct 22;17(1):158.
74. Ciceri P, Elli F, Braidotti P, Falleni M, Tosi D, Bulfamante G, Block GA, **Cozzolino M**. Iron citrate reduces high phosphate-induced vascular calcification by inhibiting apoptosis. *Atherosclerosis*. **2016** Sep 30;254:93-101. doi: 10.1016/j.atherosclerosis.2016.09.071.
75. Cianciolo G, **Cozzolino M**. FGF23 in kidney transplant: the strange case of Doctor Jekyll and Mister Hyde. *Clin Kidney J*. **2016** Oct;9(5):665-8. doi: 10.1093/ckj/sfw072. Epub 2016 Sep 6.
76. Senatore S, Galli C, Conti A, Faccini M, Cantoni S, Ciconali G, Mainardi G, Lamberti A, Dighera R, Radice Trolli F, Oggioni C, Angelini Sironi L, **Cozzolino M**, Zanetti AR, Romanò L. Hepatitis C virus outbreak in a haemodialysis unit: learning from failures. *J Hosp Infect*. **2016** Aug 23. pii: S0195-6701(16)30327-9. doi: 10.1016/j.jhin.2016.07.021. [Epub ahead of print]

77. **Cozzolino M**, Mangano M, Magagnoli L, Di Lullo L, Galassi A, Brancaccio D, Bellasi A. [Iron-based Phosphate Binders for ESRD Patients]. *G Ital Nefrol.* **2016** Jul-Aug;33(4). pii: gin/33.4.13. Italian.
78. Bellasi A, Di Lullo L, Melfa G, Minorette C, Ratti C, Campana C, Volpi M, Mangano S, Di Iorio B, **Cozzolino M**. [New oral anticoagulants (NOAC) in nephrology]. *G Ital Nefrol.* **2016** Jul-Aug;33(4). pii: gin/33.4.12. Italian.
79. Bellasi A, **Cozzolino M**, Russo D, Molony D, Di Iorio B. Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study. *Clin Nephrol.* **2016** Jul 22. [Epub ahead of print]
80. Di Lullo L, Bellasi A, Barbera V, **Cozzolino M**, Russo D, De Pascalis A, Santoboni F, Villani A, De Rosa S, Colafelice M, Russo L, Ronco C. [Acute Kidney Injury, Type - 3 cardiorenal syndrome, Biomarkers, Renal Replacement Therapy]. *G Ital Nefrol.* **2016** May-Jun;33(3). pii: gin/33.3.2. Italian.
81. Ciceri P, Elli F, Cappelletti L, Tosi D, Savi F, Bulfamante G, **Cozzolino M**. Osteonectin (SPARC) Expression in Vascular Calcification: In Vitro and Ex Vivo Studies. *Calcif Tissue Int.* **2016** Jun 23. [Epub ahead of print]
82. Cianciolo G, Galassi A, Capelli I, Angelini ML, La Manna G, **Cozzolino M**. Vitamin D in Kidney Transplant Recipients: Mechanisms and Therapy. *Am J Nephrol.* **2016** May 28;43(6):397-407.
83. Di Lullo L, Rivera R, Barbera V, Bellasi A, **Cozzolino M**, Russo D, De Pascalis A, Banerjee D, Floccari F, Ronco C. Sudden cardiac death and chronic kidney disease: From pathophysiology to treatment strategies. *Int J Cardiol.* **2016** May 3;217:16-27.
84. Morrone LF, Bolasco P, Camerini C, Cianciolo G, Cupisti A, Galassi A, Mazzaferro S, Russo D, Russo L, **Cozzolino M**. Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology. *J Nephrol.* **2016** Apr 9. [Epub ahead of print] Review.
85. **Cozzolino M**, Elli F, Carugo S, Ciceri P. Secondary Hyperparathyroidism in End-Stage Renal Disease: No Longer a Matter for Surgeons? *Blood Purif.* **2016** Apr 2;42(1):44-48. [Epub ahead of print]
86. Brandenburg VM, Evenepoel P, Floege J, Goldsmith D, Kramann R, Massy Z, Mazzaferro S, Schurgers LJ, Sinha S, Torregrosa V, Ureña-Torres P, Vervloet M, **Cozzolino M**; ERA-EDTA Working Group on CKD-MBD and EUCALNET. Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis? *Nephrol Dial Transplant.* **2016** Mar 22. pii: gfw025. [Epub ahead of print]
87. Cianciolo G, Capelli I, Cappuccilli M, Schillaci R, **Cozzolino M**, La Manna G. Calcifying circulating cells: an uncharted area in the setting of vascular calcification in CKD patients. *Clin Kidney J.* **2016** Apr;9(2):280-6.
88. Centola M, Lucreziotti S, Salerno-Uriarte D, Sponzilli C, Ferrante G, Acquaviva R, Castini D, Spina M, Lombardi F, **Cozzolino M**, Carugo S. A comparison between two different definitions of contrast-induced acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Int J Cardiol.* **2016** Feb 17;210:4-9.
89. **Cozzolino M**, Carugo S. Low Dialysate Calcium: Between Low Arterial Calcification and Improved Low Bone Turnover. *Blood Purif.* **2016** Feb 23;42(1):1-2.
90. Russo D, Capuano A, **Cozzolino M**, Napolitano P, Mosella F, Russo L, Saviano C, Zoccali C. Multimodal treatment of calcific uraemic arteriopathy (calciphylaxis): a case series. *Clin Kidney J.* **2016** Feb;9(1):108-12.

91. Malindretos P, **Cozzolino M**. Phosphate Binders, Past - Present - Future. A critical appraisal. *Expert Opin Pharmacother*. **2015** Dec 17. [Epub ahead of print]
92. **Cozzolino M**, Pasquali M. Where is the link between mineral bone markers and cardiovascular disease in CKD? *Clin Kidney J*. **2015** Dec;8(6):729-731. Epub 2015Oct 19.
93. **Cozzolino M**, Covic A, Martinez-Placencia B, Xynos K. Treatment Failure of Active Vitamin D Therapy in Chronic Kidney Disease: Predictive Factors. *Am J Nephrol*. **2015** Oct 7;42(3):228-236.
94. Brandenburg V, Adragao T, van Dam B, Evenepoel P, Frazão JM, Ketteler M, Mazzaferro S, Urena Torres P, Ramos R, Torregrosa JV, **Cozzolino M**. Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). *Clin Kidney J*. **2015** Oct;8(5):567-71. doi: 10.1093/ckj/sfv056. Epub 2015 Jul 6. Review.
95. Ciceri P, Elli F, Cappelletti L, Tosi D, Braidotti P, Bulfamante G, **Cozzolino M**. A new in vitro model to delay high phosphate-induced vascular calcification progression. *Mol Cell Biochem*. **2015** Sep 7. [Epub ahead of print]
96. Di Lullo L, Barbera V, Santoboni A, Bellasi A, **Cozzolino M**, De Pascalis A, Rivera R, Balducci A, Russo D, Ronco C. [Troponins and chronic kidney disease]. *G Ital Nefrol*. **2015** Jul-Aug;32(4). pii: gin/32.4.1. Italian.
97. Bover J, Ureña P, Ruiz-García C, daSilva I, Lescano P, Del Carpio J, Ballarín J, **Cozzolino M**. Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. *Clin J Am Soc Nephrol*. **2015** Jul 29. pii: CJN.01760215. [Epub ahead of print] Review.
98. Messa P, **Cozzolino M**, Brancaccio D, Cannella G, Malberti F, Costanzo AM, di Luzio Paparatti U, Festa V, Gualberti G, Mazzaferro S; FARO Study Group. Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study. *BMC Nephrol*. **2015** Feb 6;16(1):11.
99. Galassi A, **Cozzolino M**. Magnesium: a renewed player of vascular ageing in diabetic CKD patients? *Clin Kidney J*. **2014** Apr;7(2):93-6. doi: 10.1093/ckj/sfu011. Epub 2014 Feb 28.
100. **Cozzolino M**. New endocrine biomarkers and cardiovascular disease: is it time for routinely screening? *Clin Chem Lab Med*. **2015** Mar 14. pii: /j/cclm.ahead-of-print/cclm-2015-0168/cclm-2015-0168.xml. doi: 10.1515/cclm-2015-0168. [Epub ahead of print]
101. Goldsmith D, Covic A, Vervloet M, **Cozzolino M**, Nistor I; Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) working group and the European Renal Best Practice (ERBP) advisory board; Chronic Kidney Disease-Mineral Bone Disease CKD-MBD working group and the European Renal Best Practice ERBP advisory board. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. *Nephrol Dial Transplant*. **2015** May;30(5):698-700. Epub 2015 Mar 4.
102. Morrone LF, **Cozzolino M**. The beneficial impact of vitamin D treatment in CKD patients: what's next? *Clin Kidney J*. **2015** Feb;8(1):38-40.
103. Bover J, Evenepoel P, Ureña-Torres P, Vervloet MG, Brandenburg V, Mazzaferro S, Covic A, Goldsmith D, Massy ZA, **Cozzolino M**; CKD-MBD Working Group of ERA-EDTA. Opponent's comments. *Nephrol Dial Transplant*. **2015** Mar;30(3):357.
104. Bover J, Evenepoel P, Ureña-Torres P, Vervloet MG, Brandenburg V, Mazzaferro S, Covic A, Goldsmith D, Massy ZA, **Cozzolino M**; CKD-MBD Working Group of ERA-EDTA. Pro: Cardiovascular calcifications are clinically relevant. *Nephrol Dial Transplant*. **2015** Mar;30(3):345-51.

105. **Cozzolino M**, Tomlinson J, Walsh L, Bellasi A. Emerging drugs for secondary hyperparathyroidism. *Expert Opin Emerg Drugs*. **2015** Feb 23;1-12.
106. **Cozzolino M**, Funk F, Rakov V, Phan O, Teitelbaum I. Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide. *Curr Drug Metab*. **2015** Feb 6. [Epub ahead of print]
107. **Cozzolino M**. A Renewed Question in Haemodialysis Patients: Should We Correct Low Serum Magnesium Levels? *Blood Purif*. **2015** Jan 6;38(3-4):242-243.
108. **Cozzolino M**. The link between vitamin D, parathyroid hormone, and cardiovascular disease. *J Cardiovasc Med (Hagerstown)*. **2015** Jan;16(1):69-70
109. Roggeri DP, **Cozzolino M**, Mazzaferro S, Brancaccio D, Paoletti E, Roggeri A, Costanzo AM, di Luzio Paparatti U, Festa V, Messa P. Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study. *Int J Nephrol Renovasc Dis*. **2014** Dec 16;8:1-6. eCollection 2015.
110. Brandenburg VM, **Cozzolino M**, Mazzaferro S. Calcific Uremic Arteriopathy: A Call for Action. *Semin Nephrol*. **2014** Nov;34(6):641-647.
111. Olauson H, Vervloet MG, **Cozzolino M**, Massy ZA, Ureña Torres P, Larsson TE. New Insights Into the FGF23-Klotho Axis. *Semin Nephrol*. **2014** Nov;34(6): 586-597. doi: 10.1016/j.semnephrol.2014.09.005. Review.
112. **Cozzolino M**, Evenepoel P, Covic A. Introduction: mineral bone disorder is a key player in chronic kidney disease. *Semin Nephrol*. **2014** Nov;34(6):577. doi: 10.1016/j.semnephrol.2014.09.002.
113. **Cozzolino M**, Messa P, Brancaccio D, Cannella G, Bolasco P, Di Luca M, Costanzo AM, di Luzio Paparatti U, Festa V, Gualberti G, Mazzaferro S. Achievement of NKF/K-DOQI Recommended Target Values for Bone and Mineral Metabolism in Incident Hemodialysis Patients: Results of the FARO-2 Cohort. *Blood Purif*. **2014** Sep 27;38(1):37-45. [Epub ahead of print]
114. Galassi A, Cupisti A, Santoro A, **Cozzolino M**. Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool. *J Nephrol*. **2014** Sep 23. [Epub ahead of print]
115. **Cozzolino M**. Which outcome in chronic kidney disease-mineral and bone disorder patients? *Nephrourol Mon*. **2014** Apr 28;6(3):e18662.
116. Russo R, Ruospo M, **Cozzolino M**, De Nicola L, Icardi A, Paoletti E, Mazzaferro S. Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review. *J Nephrol*. **2014** Jul 11. [Epub ahead of print]
117. Fouque D, Horne R, **Cozzolino M**, Kalantar-Zadeh K. Balancing Nutrition and Serum Phosphorus in Maintenance Dialysis. *Am J Kidney Dis*. **2014** Mar 12. doi:p11: S0272-6386(14)00523-X. 10.1053/j.ajkd.2014.01.429. [Epub ahead of print]
118. Vervloet MG, Massy ZA, Brandenburg VM, Mazzaferro S, **Cozzolino M**, Ureña-Torres P, Bover J, Goldsmith D; on behalf of the CKD-MBD Working Group of ERA-EDTA. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. *Lancet Diabetes Endocrinol*. **2014** May;2(5):427-436.
119. **Cozzolino M**, Urena-Torres P, Vervloet M, Brandenburg V, Bover J, Goldsmith D, Larsson TE, Massy ZA, Mazzaferro S. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? *Nephrol Dial Transplant* **2014** Feb 9. [Epub ahead of print]
120. **Cozzolino M**, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with

- secondary hyperparathyroidism receiving hemodialysis: results of the IMPACT-SHPT study. *Nephrol Dial Transplant*. 2014 Feb 4. [Epub ahead of print]
121. Maioli C, **Cozzolino M**, Gallieni M, Sole AD, Tagliabue L, Strinchini A, Gaito S, Lecchi M, Cusi D, Lucignani G. Evaluation of renal function in elderly patients: performance of creatinine-based formulae versus the isotopic method using <sup>99m</sup>Tc-diethylene triamine pentaacetic acid. *Nucl Med Commun*. 2013 Dec 26. [Epub ahead of print]
  122. Carrero JJ, **Cozzolino M**. Nutritional Therapy, Phosphate Control and Renal Protection. *Nephron Clin Pract*. 2014 Jan 11;126(1):1-7. [Epub ahead of print]
  123. Icardi A, Sacco P, Tarroni A, Cappelletti L, **Cozzolino M**. [Role of inflammation on renal anaemia]. *G Ital Nefrol*. 2013 Nov-Dec;30(6). doi:pii: gin/30.6.13. Italian.
  124. Santorelli G, Bellasi A, Salari P, Lo Cicero A, Del Giudice L, Venturelli C, Francesco N, **Cozzolino M**, Galassi A. [A case of encapsulating peritoneal sclerosis after fifteen years of peritoneal dialysis with a favorable outcome]. *G Ital Nefrol*. 2013 Nov-Dec;30(6). doi:pii: gin/30.6.9. Italian.
  125. Locatelli F, Messa P, Bellasi A, **Cozzolino M**, Di Luca M, Garibotto G, Gesualdo L, Malberti F, Massimetti C, Mazzaferro S, Mereu MC, Morosetti M, Morrone LF, Panuccio V, Rapisarda F, Russo D, Schinella D. [What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study results]. *G Ital Nefrol*. 2013 Sep-Oct;30(5). doi:pii: gin/30.5.4. Italian.
  126. Krueger T, Schlieper G, Schurgers L, Cornelis T, **Cozzolino M**, Jacobi J, Jadoul M, Ketteler M, Rump LC, Stenvinkel P, Westenfeld R, Wiecek A, Reinartz S, Hilgers RD, Floege J. Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. *Nephrol Dial Transplant*. 2013 Nov 26. [Epub ahead of print]
  127. Foletti A, **Cozzolino M**. [A biophysical integrated approach to autoimmune nephrotic syndrome: case report.]. *Recenti Prog Med*. 2013 Sep;104(9):488-489.
  128. Galassi A, Bellasi A, Auricchio S, Papagni S, **Cozzolino M**. Which Vitamin D in CKD-MBD? The Time of Burning Questions. *Biomed Res Int*. 2013;2013:864012. Epub 2013 Aug 7.
  129. Minutolo R, Conte G, **Cozzolino M**, Polito P, Manno C, Di Iorio BR, Santoro D, Di Luca M, Nappi F, Feriozzi S, Sasso FC, De Nicola L. Conversion from Epoetin and Darbepoetin to C.E.R.A. in Non-Dialysis CKD Patients: A Multicenter Italian Prospective Study in Nephrology Practice. *Blood Purif*. 2013 Aug 28;36(2):69-77.
  130. **Cozzolino M**. Prevention and Treatment of CKD-MBD. *Nephrourol Mon*. 2013 Spring; 5(2):773-4.
  131. Bellasi A, Galassi A, Papagni S, **Cozzolino M**. Cardiac valve calcification: an immutable pathologic finding in chronic kidney disease? *J Nephrol*. 2013 Jun 28:0. doi: 10.5301/jn.5000291. [Epub ahead of print]
  132. Bellasi A, Galassi A, Salvi P, **Cozzolino M**. Paricalcitol and Cardiorenal Outcome: From the IMPACT Study to Clinical Practice. *Blood Purif*. 2013 May 25;36(1):12-16.
  133. Bover J, Dasilva I, Furlano M, Lloret MJ, Díaz-Encarnación MM, Ballarín J, **Cozzolino M**. Clinical uses of 1,25-dihydroxy-19-nor-vitamin D2 (Paricalcitol). *Curr Vasc Pharmacol*. 2013 May 16. [Epub ahead of print]
  134. Mazzaferro S, Goldsmith D, Larsson TE, Massy ZA, **Cozzolino M**. Vitamin D Metabolites and/or Analogs: Which D for Which Patient? *Curr Vasc Pharmacol*. 2013 May 16. [Epub ahead of print]

135. Mazzaferro S, **Cozzolino M**. Vitamin D Therapy: An Update. *Curr Vasc Pharmacol*. 2013 May 16. [Epub ahead of print]
136. **Cozzolino M**, Gentile G, Mazzaferro S, Brancaccio D, Ruggerenti P, Remuzzi G. Blood Pressure, Proteinuria, and Phosphate as Risk Factors for Progressive Kidney Disease: A Hypothesis. *Am J Kidney Dis*. 2013 May 9. [Epub ahead of print]
137. Ciceri P, Elli F, Brenna I, Volpi E, Brancaccio D, **Cozzolino M**. The Calcimimetic Calindol Prevents High Phosphate-Induced Vascular Calcification by Upregulating Matrix GLA Protein. *Nephron Exp Nephrol*. 2013 Mar 28;122(3-4):75-82.
138. Bellasi A, **Cozzolino M**, Adragao T, Di Iorio B, Russo D. Phosphate binders in moderate chronic kidney disease: where do we stand? *J Nephrol*. 2013 Mar 25:0. doi: 10.5301/jn.5000258. [Epub head of print]
139. Icardi A, Paoletti E, De Nicola L, Mazzaferro S, Russo R, **Cozzolino M**. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. *Nephrol Dial Transplant*. 2013 Mar 6. [Epub ahead of print]
140. **Cozzolino M**, Brunini F, Capone V, Ricca F, Kwaidri Y, Montanari E, Cusi D. [Role of vitamin D in the pathogenesis of chronic kidney disease]. *Recenti Prog Med*. 2013 Jan;104(1):33-40
141. Ciceri P, Elli F, Brenna I, Volpi E, Romagnoli S, Tosi D, Braidotti P, Brancaccio D, **Cozzolino M**. Lanthanum Prevents High Phosphate-Induced Vascular Calcification by Preserving Vascular Smooth Muscle Lineage Markers. *Calcif Tissue Int*. 2013 Feb 17. [Epub ahead of print]
142. **Cozzolino M**, Rizzo MA, Stucchi A, Cusi D, Gallieni M. Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. *Ther Adv Chronic Dis*. 2012 Mar;3(2):59-68. doi: 10.1177/2040622311433771.
143. **Cozzolino M**, Bruschetta E, Cusi D, Montanari E, Giovenzana ME, Galassi A. Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate. *Expert Opin Pharmacother*. 2012 Oct 4. [Epub ahead of print]
144. Roggeri D, Mazzaferro S, Brancaccio D, Cannella G, Messa P, Di Luca M, Morosetti M, Costanzo AM, di Luzio Paparatti U, Cornago D, **Cozzolino M**; on behalf of the FARO Study Group.. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study. *J Med Econ*. 2012 Jun 17. [Epub ahead of print]
145. Bover J, Lloret MJ, Dasilva I, Furlano M, Díaz M, Herreros A, **Cozzolino M**, Ballarín J. Role of vitamin d receptor activators in peritoneal dialysis. *Contrib Nephrol*. 2012;178:124-42.
146. **Cozzolino M**, Stucchi A, Rizzo MA, Brenna I, Elli F, Ciceri P, Bover J, Cusi D, Gallieni M. Phosphate control in peritoneal dialysis. *Contrib Nephrol*. 2012;178:116-23.
147. **Cozzolino M**, Stucchi A, Rizzo MA, Soldati L, Cusi D, Ciceri P, Brenna I, Elli F, Gallieni M. Vitamin D receptor activation and prevention of arterial ageing. *Nutr Metab Cardiovasc Dis*. 2012 May 24. [Epub ahead of print]
148. **Cozzolino M**. [FGF-23 causes left ventricular hypertrophy!]. *G Ital Nefrol*. 2012 Mar;29(2):142. Italian
149. **Cozzolino M**, Brancaccio D, Cannella G, Messa P, Gesualdo L, Marangella M, Lodeserto C, Pozzato M, Rombolà G, Costanzo AM, di Luzio Paparatti U, Mazzaferro S; on behalf of the FARO Study Group. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH  $\leq 150$  pg/mL: results of the Italian FARO Survey. *Nephrol Dial Transplant*. 2012 Apr 20. [Epub ahead of print]



150. Ketteler M, Martin KJ, Wolf M, Amdahl M, **Cozzolino M**, Goldsmith D, Sharma A, Marx S, Khan S. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. *Nephrol Dial Transplant*. 2012 Mar 2. [Epub ahead of print]
151. Costanzo MR, **Cozzolino M**, Aspromonte N, Mistrorigo F, Valle R, Ronco C. Extracorporeal ultrafiltration in heart failure and cardio-renal syndromes. *Semin Nephrol*. 2012 Jan;32(1):100-11.
152. **Cozzolino M**, Bruschetta E, Stucchi A, Ronco C, Cusi D. Role of vitamin d receptor activators in cardio-renal syndromes. *Semin Nephrol*. 2012 Jan;32(1):63-9.
153. Ciceri P, Volpi E, Brenna I, Elli F, Borghi E, Brancaccio D, **Cozzolino M**. The combination of lanthanum chloride and the calcimimetic calindol delays the progression of vascular smooth muscle cells calcification. *Biochem Biophys Res Commun*. 2012 Jan 28. [Epub ahead of print]
154. Bover J, **Cozzolino M**. Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation. *Kidney Int Suppl* (2011). 2011 Sep;1(4):122-129. Review.
155. **Cozzolino M**. The calciotropic hormones PTH and vitamin D: from bone to blood vessels. *J Intern Med*. 2011 Dec 28. doi: 10.1111/j.1365-2796.2011.02501.x. [Epub ahead of print]
156. Vezzoli G, Terranegra A, Rainone F, Arcidiacono T, **Cozzolino M**, Aloia A, Dogliotti E, Mingione A, Cusi D, Soldati L. Calcium-sensing receptor and calcium kidney stones. *J Transl Med*. 2011 Nov 22;9(1):201.
157. **Cozzolino M**. [Prevention of vascular calcification: the role of magnesium.]. *G Ital Nefrol*. 2011 Sep;28(5):472. Italian.
158. Ketteler M, Martin KJ, **Cozzolino M**, Goldsmith D, Sharma A, Khan S, Dumas E, Amdahl M, Marx S, Audhya P. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. *Nephrol Dial Transplant*. 2011 Sep 19. [Epub ahead of print]
159. Jongbloed F, Galassi A, **Cozzolino M**, Zietse R, Chiarelli G, Cusi D, Brancaccio D, Gallieni M. Clinical significance of FGF-23 measurement in dialysis patients. *Clin Nephrol*. 2011 Sep;76(3):201-209.
160. Mazzaferro S, Pasquali M, **Cozzolino M**. Treatment of Cardiovascular Calcification in Uremia. *Curr Vasc Pharmacol*. 2011 Aug 9. [Epub ahead of print]
161. **Cozzolino M**, Galassi A, Apetrii M, Covic A. What would we like to know, and what do we not know about fibroblast growth factor 23. *J Nephrol*. 2011 Jul 15. pii: 472E0A95-4E96-4657-A88B-CB67D6F5309B. doi: 10.5301/jn.5000003. [Epub ahead of print]
162. Brancaccio D, **Cozzolino M**. CKD-MBD: an endless story. *J Nephrol*. 2011 May-Jun;24 Suppl 18:S42-8..
163. **Cozzolino M**, Mazzaferro S, Messa P. New insights into the role of calcium-sensing receptor activation. *J Nephrol*. 2011 May-Jun;24 Suppl 18:S38-41.
164. **Cozzolino M**, Brenna I, Ciceri P, Volpi E, Cusi D, Brancaccio D. Vascular calcification in chronic kidney disease: a changing scenario. *J Nephrol*. 2011 May-Jun;24 Suppl 18:S3-10.
165. **Cozzolino M**, Ronco C. The impact of paricalcitol on left ventricular hypertrophy. *Contrib Nephrol*. 2011;171:161-5.

166. **Cozzolino M**, Brenna I, Volpi E, Ciceri P, Mehmeti F, Cusi D. Restoring the physiology of vitamin d receptor activation and the concept of selectivity. *Contrib Nephrol.* **2011**;171:151-6.
167. Brancaccio D, **Cozzolino M**, Cannella G, Messa P, Bonomini M, Cancarini G, Caruso MR, Cascone C, Costanzo AM, di Luzio Paparatti U, Mazzaferro S. Secondary Hyperparathyroidism in Chronic Dialysis Patients: Results of the Italian FARO Survey on Treatment and Mortality. *Blood Purif.* **2011** May 28;32(2):124-132.
168. Ciceri P, Volpi E, Brenna I, Arnaboldi L, Neri L, Brancaccio D, **Cozzolino M**. Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation. *Nephrol Dial Transplant.* **2011** May 25. [Epub ahead of print]
169. **Cozzolino M**, Mehmeti F, Ciceri P, Volpi E, Stucchi A, Brenna I, Cusi D. The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control. *Int J Nephrol.* **2011**; 2011: 269060.
170. **Cozzolino M**. [When is calcium bad for CKD patients?]. *G Ital Nefrol.* **2011** Jan-Feb;28(1):9. Italian.
171. Brandenburg VM, **Cozzolino M**, Ketteler M. Calciphylaxis: a still unmet challenge. *J Nephrol.* **2011** Feb 20. [Epub ahead of print]
172. Ronco C, **Cozzolino M**. Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes. *Heart Fail Rev.* **2011** Feb 13. [Epub ahead of print]
173. Gallieni M, Chiarelli G, Olivi L, **Cozzolino M**, Cusi D. Unsuccessful application of taurolidine in the treatment of fungal peritonitis in peritoneal dialysis. *Clin Nephrol.* **2011** Jan;75(1):70-3.
174. **Cozzolino M**, Mehmeti F, Bonelli F, Ronga C, Musetti C, Missaglia E, Stucchi A, Colombo F, Tavecchia M, Cuoccio P, Brenna I, Volpi E, Ciceri P, Cusi D. Cardioprotective effect of vitamin D in nondialyzed patients with stage 3-5 CKD. *G Ital Nefrol* **2010**; 27 (S52): S27-S31.
175. **Cozzolino M**, Missaglia E, Ortiz A, Bellasi A, Adragao T, Apostolou T, Vescovo G, Gallieni M. Vascular calcification in chronic kidney disease. *Recenti Prog Med* **2010**; 101: 442-452.
176. **Cozzolino M**, Mazzaferro S, Brandenburg V. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders? *Nephrol Dial Transplant.* **2010** Nov 15. [Epub ahead of print]
177. **Cozzolino M**, Biondi ML, Banfi E, Riser BL, Mehmeti F, Cusi D, Gallieni M. CCN2 (CTGF) Gene Polymorphism Is a Novel Prognostic Risk Factor for Cardiovascular Outcomes in Hemodialysis Patients. *Blood Purif.* **2010** Nov 11; 30(3): 272-276. [Epub ahead of print]
178. **Cozzolino M**. The Control of Hyperphosphatemia in Renal Failure: Between Vascular Calcification and Inflammation. *Blood Purif.* **2010** Sep 21;30(3):159-160. [Epub ahead of print]
179. **Cozzolino M**. [VDR and CaSR: from parathyroids to arteries.]. *G Ital Nefrol.* **2010** July-August;27(4):334. Italian.
180. Pontoriero G, **Cozzolino M**, Locatelli F, Brancaccio D. CKD Patients: The Dilemma of Serum PTH Levels. *Nephron Clin Pract.* **2010** Jul 16;116(4):c263-c268. [Epub ahead of print]
181. **Cozzolino M**, Ketteler M, Zehnder D. The vitamin D system: a crosstalk between the heart and kidney. *Eur J Heart Fail.* **2010** Jul 6. [Epub ahead of print]

182. **Cozzolino M**, Ronga C, Cusi D. [Anticoagulant therapy in patients with atrial fibrillation on dialysis: between the risk of hemorrhage and vascular calcification.]. *G Ital Nefrol.* **2010** May-Jun;27(3):237-9. Italian.
183. Gallieni M, Olivi L, Mezzina N, **Cozzolino M**, Cusi D. [Renal effects of combined anti-hypertensive treatments]. *Recenti Prog Med.* **2010** Feb;101(2):70-7. Italian.
184. **Cozzolino M**, Malindretos P. The role of vitamin d receptor activation in chronic kidney disease. *Hippokratia.* **2010** Jan;14(1):7-9.
185. **Cozzolino M**, Biondi ML, Galassi A, Cusi D, Brancaccio D, Gallieni M. Vascular Calcification and Cardiovascular Outcome in Dialysis Patients: The Role of Gene Polymorphisms. *Blood Purif.* **2010** Mar 31;29(4):347-351. [Epub ahead of print]
186. **Cozzolino M**, Brandenburg V. Warfarin: to use or not to use in chronic kidney disease patients? *J Nephrol.* **2010** Nov-Dec;23(6):648-52.
187. **Cozzolino M**, Mazzaferro S. The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone And Renal Disease. *Curr Vasc Pharmacol.* **2010** May 1;8(3):404-11
188. **Cozzolino M**, Olivi L, Volpi E, Ciceri P, Brancaccio D. [Prevention and treatment of secondary hyperparathyroidism in non-dialyzed patients with stage 3-5 chronic kidney disease]. *G Ital Nefrol* **2009**. November-December;26(S-49):30-35. Italian.
189. Brancaccio D, **Cozzolino M**. [Cardiovascular effects of VDR and CaSR activation]. *G Ital Nefrol.* **2009**. November-December; 26(S-49):18-22. Italian.
190. **Cozzolino M**, Mazzaferro S. [Introduction to new aspects of the pathophysiology, prevention and treatment of CKD-MBD]. *G Ital Nefrol.* **2009**. November-December; 26(S-49):1. Italian.
191. **Cozzolino M**. [KDIGO on CKD-MBD: a new classification for an old problem]. *G Ital Nefrol.* 2009 November-December;26(6):645. Italian.
192. **Cozzolino M**. [Vascular calcifications in patients with kidney disease: the hypothesis of the three "culprits"]. *G Ital Nefrol.* **2009** September-October;26(5):562. Italian.
193. **Cozzolino M**. Emerging Roles for Osteoprotegerin and Receptor Activator of Nuclear Factor-kappa B in the Vascular System. *Blood Purif.* **2009** Sep 1;28(4):346-347.
194. Brancaccio D, Bellasi A, **Cozzolino M**, Galassi A, Gallieni M. Arterial accelerated aging in dialysis patients: the clinical impact of vascular calcification. *Curr Vasc Pharmacol.* **2009** Jul;7(3):374-80.
195. **Cozzolino M**, Gallieni M, Pasho S, Fallabrino G, Ciceri P, Volpi EM, Olivi L, Brancaccio D. Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease. *Drugs Aging.* **2009**;26(6):457-68.
196. Neri L, Rocca Rey LA, Gallieni M, Brancaccio D, **Cozzolino M**, Colombi A, Burroughs TE. Occupational stress is associated with impaired work ability and reduced quality of life in patients with chronic kidney failure. *Int J Artif Organs.* **2009** May;32(5):291-8.
197. **Cozzolino M**. [FGF-23: A New Player in CKD-MBD.]. *G Ital Nefrol.* **2009** May-June;26(3):292. Italian.
198. Brancaccio D, **Cozzolino M**, Pasho S, Fallabrino G, Olivi L, Gallieni M. New Acquisitions in Therapy of Secondary Hyperparathyroidism in Chronic Kidney Disease and Peritoneal Dialysis Patients: Role of Vitamin D Receptor Activators. *Contrib Nephrol.* **2009**;163:219-226. Epub 2009 Jun 3.
199. **Cozzolino M**, Fallabrino G, Pasho S, Olivi L, Ciceri P, Volpi E, Gallieni M, Brancaccio D. Importance of Vitamin D Receptor Activation in Clinical Practice. *Contrib Nephrol.* **2009**;163:213-218. Epub 2009 Jun 3.

200. **Cozzolino M.** The role of FGF-23 in CKD patients still needs to be clarified. *Nephrol Dial Transplant.* **2009** May 27. [Epub ahead of print]
201. **Cozzolino M,** Brandenburg V. Paricalcitol and outcome: A manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U". *Clin Nephrol.* **2009** Jun;71(6):593-601.
202. **Brancaccio D,** Gallieni M, Pasho S, Fallabrino G, Olivi L, Volpi E, Ciceri P, Missaglia E, Ronga C, Brambilla C, Butti A, Rocca-Rey L, Chiarelli G, **Cozzolino M.** [Pathogenesis and treatment of vascular calcification in CKD.]. *G Ital Nefrol.* **2009** March-April;26(S-45):20-27. Italian.
203. **Morrone LF,** Mazzaferro S, Russo D, Aucella F, **Cozzolino M,** Facchini MG, Galfrè A, Malberti F, Mereu MC, Nordio M, Pertosa G, Santoro D; CPCP Study Investigators. Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients. *Nephrol Dial Transplant.* **2009** Apr 15. [Epub ahead of print]
204. **Gallieni M,** **Cozzolino M,** Fallabrino G, Pasho S, Olivi L, Brancaccio D. Vitamin D: Physiology and pathophysiology. *Int J Artif Organs.* **2009** Feb;32(2):87-94.
205. **Cozzolino M,** Pasho S, Fallabrino G, Olivi L, Gallieni M, Brancaccio D. Pathogenesis of secondary hyperparathyroidism. *Int J Artif Organs.* **2009** Feb;32(2):75-80.
206. **Cozzolino M,** Ketteler M. The link between bone and cardiovascular disease in CKD: New insights into pathogenesis and treatment. *Int J Artif Organs.* **2009** Feb;32(2):65-66.
207. **Cozzolino M.** Matrix-Gla protein and vascular calcification: The negative role of oral anticoagulant therapy. *Thromb Haemost.* **2009** Apr;101(4):605-6.
208. **Galassi A,** Brancaccio D, **Cozzolino M,** Bellinghieri G, Buon cristiani U, Cavatorta F, D'Apice L, Di Iorio B, Gesualdo L, Gianni S, Ricciardi B, Russo D, Andreucci V. Awareness of hypertension and proteinuria in randomly selected patients in 11 Italian cities. A 2005 report of the National Kidney Foundation of Italy. *J Clin Hypertens (Greenwich).* **2009** Mar;11(3):138-43.
209. **Cozzolino M,** Ciceri P, Volpi EM, Olivi L, Messa PG. Pathophysiology of Calcium and Phosphate Metabolism Impairment in Chronic Kidney Disease. *Blood Purif.* **2009** Mar 18;27(4):338-344. [Epub ahead of print]
210. **Messa P,** Cerutti R, Brezzi B, Alfieri C, **Cozzolino M.** Calcium and Phosphate Control by Dialysis Treatments. *Blood Purif.* **2009** Mar 18;27(4):360-368. [Epub ahead of print]
211. **Cozzolino M.** [CERA: Continuous Erythropoietin Receptor Activator for anemia in CKD patients.]. *G Ital Nefrol.* **2009** January-February;26(1):8. Italian.
212. **Cozzolino M,** Biondi ML, Galassi A, Turri O, Brancaccio D, Gallieni M. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients. *Nephrol Dial Transplant.* **2009** Feb 16. [Epub ahead of print]
213. **Cozzolino M,** Gallieni M, Brancaccio D. Inflammation and vascular calcification in chronic kidney disease: The role of Fetuin-A. *Cytokine.* **2009** Feb; 45 (2): 70-71.No abstract available.
214. **Cozzolino M,** Gallieni M, Brancaccio D. The mechanisms of hyperphosphatemia-induced vascular calcification. *Int J Artif Organs.* **2008** Dec;31(12):1002-3.
215. **Gallieni M,** **Cozzolino M,** Brancaccio D, Giovannini M. Renal outcomes in the ONTARGET study. *Lancet.* **2008** Dec 13;372(9655):2019; author reply 2020-1. No abstract available.

216. Chiarelli G, Beaulieu M, **Cozzolino M**, Singh S, Kiaii M, Taylor P, Levin A, Brancaccio D, Gallieni M. Vascular access planning in peritoneal dialysis patients. *Perit Dial Int.* **2008** Nov-Dec;28(6):585-90.
217. Molino C, Fabbian F, **Cozzolino M**, Longhini C. The management of viral hepatitis in CKD patients: An unresolved problem. *Int J Artif Organs.* **2008** Aug;31(8):683-96.
218. **Cozzolino M**, Brancaccio D. VDRAs versus calcimimetics: better safe than sorry? *Kidney Int.* **2008** Oct;74(7):966. No abstract available.
219. Gallieni M, **Cozzolino M**, Ronga C, Brancaccio D. Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease. *Nat Clin Pract Nephrol.* **2008** Sep;4(9):488-9. No abstract available.
220. Gallieni M, **Cozzolino M**. Calcium and phosphate: serum levels versus body balance. *Kidney Int.* **2008** Jul;74(2):246; author reply 246-7. No abstract available.
221. Arcidiacono MV, **Cozzolino M**, Spiegel N, Tokumoto M, Yang J, Lu Y, Sato T, Lomonte C, Basile C, Slatopolsky E, Dusso AS. Activator Protein 2{alpha} Mediates Parathyroid TGF-{alpha} Self-Induction in Secondary Hyperparathyroidism. *J Am Soc Nephrol.* **2008** Jun 25. [Epub ahead of print]
222. **Cozzolino M**. [Vascular calcification: which link between hyperphosphatemia and hyperglycaemia?] *G Ital Nefrol.* 2008 May-June **2008**;25(3):271. Italian.
223. **Cozzolino M**, Galassi A, Pasho S, Fallabrino G, Gallieni M, Brancaccio D. Preventive measures and new pharmacological approaches of calcium and phosphate disorders. *Contrib Nephrol.* **2008**;161:234-9.
224. **Cozzolino M**, Galassi A, Gallieni M, Brancaccio D. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol. *Curr Vasc Pharmacol.* **2008** Apr;6(2):148-53.
225. **Cozzolino M**, Brancaccio D. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism. *Expert Opin Pharmacother.* **2008** Apr;9(6):947-54.
226. **Cozzolino M**, Pasho S, Missaglia E, Crovetto C, Fallabrino G, Brancaccio D. [Therapeutic options for mineral metabolism disorders in dialysis patients: a case report.]. *G Ital Nefrol.* **2008** Mar-Apr; 25(2):234-7. Italian.
227. Gallieni M, Butti A, Guazzi M, Galassi A, **Cozzolino M**, Brancaccio D. Impaired brachial artery endothelial flow-mediated dilation and orthostatic stress in hemodialysis patients. *Int J Artif Organs.* **2008** Jan; 31(1):34-42.
228. **Cozzolino M**, Mazzaferro S, Pugliese F, Brancaccio D. Vascular calcification and uremia: what do we know? *Am J Nephrol.* **2008**;28(2):339-46. Epub 2007 Nov 29.
229. **Cozzolino M**, Brancaccio D. Is PTH a Risk Factor for Cardio-Vascular Calcifications in Haemodialysis? *Nephrol Dial Transplant.* **2008** Mar; 23(3): 1067-8. No abstract available.
230. **Cozzolino M**, Brancaccio D. Clinical consequences and novel therapy of hyperphosphatemia: lanthanum carbonate for dialysis patients. *Recent Patents Cardiovasc Drug Discov.* **2007** Jan; 2(1): 29-34.
231. **Cozzolino M**, Galassi A, Bellasi A, Gallieni M, Brancaccio D. [The bone-vasculature-axis interaction: new insights into the pathogenesis of vascular calcification.] *G Ital Nefrol.* **2007** Sep-Oct;24(5):409-14. Italian.
232. **Cozzolino M**. [Is Lanthanum carbonate safer and more effective than calcium carbonate for hyperphosphatemia in dialysis patients?] *G Ital Nefrol.* **2007** Sept-Oct;24(5):366. Italian.

233. **Cozzolino M**, Brancaccio D. Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease. *Expert Opin Emerg Drugs*. **2007** Sep;12(3):341-3.
234. **Cozzolino M**, Biondi ML, Galassi A, Gallieni M, Melzi d'Eril GV, Brancaccio D. Gene polymorphisms and Serum Alpha-2-Heremans-Schmid Levels in Italian Haemodialysis Patients. *Am J Nephrol*. **2007** Sep 11;27(6):639-642 [Epub ahead of print]
235. Memoli B, De Bartolo L, Favia P, Morelli S, Lopez LC, Procino A, Barbieri G, Curcio E, Giorno L, Esposito P, **Cozzolino M**, Brancaccio D, Andreucci VE, d'Agostino R, Drioli E. Fetuin-A gene expression, synthesis and release in primary human hepatocytes cultured in a galactosylated membrane bioreactor. *Biomaterials*. **2007** Nov;28(32):4836-44. Epub 2007 Aug 13.
236. **Cozzolino M**, Galassi A, Brancaccio D. Cinacalcet, Paricalcitol, or both? *Nephrol Dial Transplant*. **2007** Jul 10; [Epub ahead of print] No abstract available.
237. Papagni S, Mongelli N, **Cozzolino M**, Brancaccio D, Ciccolella F, Favia G. [Avascular jaw osteonecrosis in a hemodialysis patient treated with bisphosphonates.] *G Ital Nefrol*. **2007** May-Jun;24(3):230-4. Italian.
238. **Cozzolino M**, Brancaccio D. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate. *Int J Artif Organs*. **2007** Apr;30(4):293-300. Review.
239. Arcidiacono MV, **Cozzolino M**, Brancaccio D, Gallieni M, Lesma E, Carelli S, Gorio A, Di Giulio AM. A role for enhanced integrin and FAK expression in uremia-induced parathyroid hyperplasia. *J Nephrol*. **2007** Mar-Apr;20(2):228-33.
240. **Cozzolino M**. [Role of vitamin D and its analogues in dialysis patients: beyond PTH control]. *G Ital Nefrol*. **2007** Mar-Apr;24(2):107. Italian. No abstract available.
241. Brancaccio D, **Cozzolino M**, Galassi A, Chiarelli G, Butti A, Bellasi A, Rocca-Rey L, Volpi A, Anelli A, Zoni U, Fusaro M, Brambilla C, Missaglia E, Crovetto C, Russo M, Longhini C, Provenzano R, Incalcaterra F, Cerasola G, Li Vecchi M, Gallieni M. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs. *J Nephrol*. **2007** Jan-Feb;20(1):3-9. Review.
242. Mazzaferro S, **Cozzolino M**, Marangella M, Strippoli GF, Messa P. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology.] *G Ital Nefrol*. **2007** Jan-Feb;24 Suppl 37:107-24. Italian.
243. Russo D, Corrao S, Miranda I, Ruocco C, Manzi S, Elefante R, Brancaccio D, **Cozzolino M**, Biondi ML, Andreucci VE. Progression of coronary artery calcification in predialysis patients. *Am J Nephrol*. **2007**;27(2):152-8. Epub **2007** Feb 20.
244. Brancaccio D, **Cozzolino M**. Lanthanum carbonate: time to abandon prejudices? *Kidney Int*. **2007** Feb;71(3):190-2.
245. **Cozzolino M**, Brancaccio D. Lanthanum carbonate--new data on parathyroid hormone control without liver damage. *Nephrol Dial Transplant*. **2007** Feb;22(2):316-8. Epub 2006 Dec 6. No abstract available.
246. **Cozzolino M**, Gallieni M, Galassi A, Brambilla C, Brancaccio D. Phosphate overload accelerates vascular aging in uremic patients. *Heart Int*. **2006**;2(1):6.
247. **Cozzolino M**, Gallieni M, Brancaccio D, Arcidiacono T, Bianchi G, Vezzoli G. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. *J Nephrol*. **2006** Sep-Oct;19(5):566-77.

248. **Cozzolino M**, Galassi A, Biondi ML, Turri O, Papagni S, Mongelli N, Civita L, Gallieni M, Brancaccio D. Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. *Am J Nephrol*. 2006;26(5):423-9. Epub 2006 Sep 12.
249. **Cozzolino M**, Galassi A, Biondi ML, Butti A, Russo M, Longhini C, Gallieni M, Brancaccio D.
250. Decreased serum fetuin-A levels after a single haemodialysis session. *Nephrol Dial Transplant*. 2007 Jan;22(1):290-1. Epub 2006 Aug 18. No abstract available.
251. **Cozzolino M**, Gallieni M, Chiarelli G, Brancaccio D. Calcium and phosphate handling in peritoneal dialysis. *Contrib Nephrol*. 2006;150:214-25. Review.
252. Giacomini M, Iapichino G, Armani S, **Cozzolino M**, Brancaccio D, Gallieni M. How to avoid and manage a pneumothorax. *J Vasc Access*. 2006 Jan-Mar;7(1):7-14. Review.
253. **Cozzolino M**, Gallieni M, Brancaccio D. Vascular calcification in uremic conditions: new insights into pathogenesis. *Semin Nephrol*. 2006 Jan;26(1):33-7. Review.
254. **Cozzolino M**, Butti A, Chiarelli G, Rocca-Rey L, Bellasi A, Galassi A, Gallieni M, Brancaccio D. [New insights in the pathogenesis of secondary hyperparathyroidism]. *G Ital Nefrol*. 2005 Jul-Aug;22(4):329-36. Review. Italian.
255. Ferrario VF, Sforza C, Dellavia C, Galassi A, Rocca Rey L, Chiarelli G, **Cozzolino M**, Gallieni M, Brancaccio D. Facial changes in adult uremic patients on chronic dialysis: possible role of
256. Brancaccio D, Biondi ML, Gallieni M, Turri O, Galassi A, Cecchini F, Russo D, Andreucci V, **Cozzolino M**. Matrix GLA protein gene polymorphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients. *Am J Nephrol*. 2005 Nov-Dec;25(6):548-52. Epub 2005 Oct 5.
257. Neri L, Gallieni M, **Cozzolino M**, Rocca-Rey L, Brambilla G, Colombi A, Foa V, Brancaccio D. Work ability and health status in dialysis patients. *Int J Artif Organs*. 2005 Jun;28(6):554-6. No abstract available.
258. **Cozzolino M**, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. *Kidney Int*. 2005 Aug;68(2):429-36. Review.
259. **Cozzolino M**, Lu Y, Sato T, Yang J, Suarez IG, Brancaccio D, Slatopolsky E, Dusso AS. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. *Am J Physiol Renal Physiol*. 2005 Nov;289(5):F1096-102. Epub 2005 Jul 5.
260. Brancaccio D, **Cozzolino M**. The mechanism of calcium deposition in soft tissues. *Contrib Nephrol*. 2005;149:279-86. Review.
261. **Cozzolino M**, Galassi A, Bellasi A, Butti A, Zoni U, Gallieni M, Brancaccio D. [Prevention of extraskkeletal calcifications in uremia] *G Ital Nefrol*. 2005 Jan-Feb;22 Suppl 31:S53-5. Review. Italian.
262. **Cozzolino M**, Butti A, Chiarelli G, Rocca-Rey L, Santagostino G, Gallieni M, Brancaccio D. [Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease] *Ital Heart J Suppl*. 2005 Jan;6(1):25-8. Review. Italian.
263. **Cozzolino M**, Brancaccio D, Gallieni M, Galassi A, Slatopolsky E, Dusso A. Pathogenesis of parathyroid hyperplasia in renal failure. *J Nephrol*. 2005 Jan-Feb;18(1):5-8.
264. Dusso A, **Cozzolino M**, Lu Y, Sato T, Slatopolsky E. 1,25-Dihydroxyvitamin D downregulation of TGFalpha/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure. *J Steroid Biochem Mol Biol*. 2004 May;89-90(1-5):507-11. Review.

265. **Cozzolino M**, Gallieni M, Corsi C, Bastagli A, Brancaccio D. Management of calcium refilling post-parathyroidectomy in end-stage renal disease. *J Nephrol.* **2004** Jan-Feb;17(1):3-8. Review.
266. Brancaccio D, **Cozzolino M**, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. *J Am Soc Nephrol.* **2004** Jan;15 Suppl 1:S21-4. Review.
267. **Cozzolino M**, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. *Kidney Int.* **2003** Nov;64(5):1653-61.
268. Brancaccio D, Di Leo C, Bestetti A, Carpani P, Tagliabue L, **Cozzolino M**, Galassi A, Tarolo G, Gallieni M. Severe cortical and trabecular osteopenia in secondary hyperparathyroidism. *Hemodial Int.* **2003** Apr 1;7(2):122-9.
269. Brancaccio D, **Cozzolino M**, Galassi A, Bellasi A, Carpani P, Gallieni M. [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient] *G Ital Nefrol.* **2003** May-Jun;20 Suppl 22:S12-6. Review. Italian.
270. Slatopolsky E, **Cozzolino M**, Lu Y, Finch J, Dusso A, Staniforth M, Wein Y, Webster J. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. *Kidney Int.* **2003** Jun;63(6):2020-7.
271. **Cozzolino M**, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. *AIDS.* **2003** Mar 7;17(4):513-20.
272. Di Leo C, Gallieni M, Bestetti A, Tagliabue L, **Cozzolino M**, Carpani P, Pozzato C, Tarolo GL, Brancaccio D. Cardiac and pulmonary calcification in a hemodialysis patient: partial regression 4 years after parathyroidectomy. *Clin Nephrol.* **2003** Jan;59(1):59-63.
273. Brancaccio D, **Cozzolino M**, Gorio A, Di Giulio AM, Gallieni M. Bone disease in uremic patients: advances in PTH suppression. *J Nephrol.* **2002** Nov-Dec;15 Suppl 6:S86-93. Review.
274. Slatopolsky E, **Cozzolino M**, Finch JL. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. *Kidney Int.* **2002** Oct;62(4):1277-84.
275. **Cozzolino M**, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, Slatopolsky E. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. *J Am Soc Nephrol.* **2002** Sep;13(9):2299-308.
276. Cordero JB, **Cozzolino M**, Lu Y, Vidal M, Slatopolsky E, Stahl PD, Barbieri MA, Dusso A. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. *J Biol Chem.* **2002** Oct 11;277(41):38965-71. Epub 2002 Aug 13.
277. **Cozzolino M**, Lu Y, Finch J, Slatopolsky E, Dusso AS. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. *Kidney Int.* **2001** Dec;60(6):2109-17.
278. **Cozzolino M**, Dusso AS, Slatopolsky E. Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. *J Am Soc Nephrol.* **2001** Nov;12(11):2511-6. Review. No abstract available.
279. Gallieni M, **Cozzolino M**, Carpani P, Zoni U, Brancaccio D. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients. *J Nephrol.* **2001** May-Jun;14(3):176-83.



280. Gallieni M, **Cozzolino M**, Brancaccio D. Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder. *Kidney Int.* **2000** Apr;57(4):1776-7. No abstract available.
281. Gallieni M, **Cozzolino M**, Zoni U. Hemodialysis access recirculation measured with a simple and economical potassium-based dilutional method. *J Vasc Access.* **2000** July - September;1(3):116-117.
282. Gallieni M, Brancaccio D, Antonucci F, Bellinghieri G, Carpani P, **Cozzolino M**, D'Agostino F, Del Mastro G, Mallamace A, Memoli B. Twice versus thrice weekly administration of intravenous calcitriol in dialysis patients: a randomized prospective trial. Gruppo Italiano di Studio dell'Osteodistrofia Renale. *Clin Nephrol.* **2000** Mar;53(3):188-93.
283. Brancaccio D, Bellotti V, Losi B, Padovese P, **Cozzolino M**, Carpani P, Mangione P, Giorgetti S, Gallieni M. Effects of a vitamin E-modified dialyzer (Excebrane) on beta-2-microglobulin structure and removal. *Contrib Nephrol.* **1999**;127:147-55. No abstract available.
284. Gallieni M, Braidotti P, **Cozzolino M**, Romagnoli S, Carpani P. Acute tubulo-interstitial nephritis requiring dialysis associated with intermittent rifampicin use: case report. *Int J Artif Organs.* **1999** Jul;22(7):477-81.
285. Gallieni M, Brancaccio D, **Cozzolino M**, Sabbioni E. Trace elements in renal failure: are they clinically important? *Nephrol Dial Transplant.* **1996** Jul;11(7):1232-5. Review. No abstract available.
286. Brancaccio D, Gallieni M, **Cozzolino M**. Treatment of hyperparathyroidism--why is it crucial to control serum phosphate? *Nephrol Dial Transplant.* **1996** Mar;11(3):420-3. Review. No abstract available.
287. Brancaccio D, **Cozzolino M**, Gallieni M. Dialysis amyloidosis: clinical aspects and therapeutic approach. *Nephrol Dial Transplant.* **1996**;11 Suppl 3:102-5. Review. No abstract available.
288. Gallieni M, **Cozzolino M**. Uncomplicated central vein catheterization of high risk patients with real time ultrasound guidance. *Int J Artif Organs.* **1995** Mar;18(3):117-21.

Data

29/04/2020

Luogo

Milano